Zobrazeno 1 - 10
of 672
pro vyhledávání: ''
Autor:
Chana Weinstock, Laleh Amiri-Kordestani, Xiao Hong Chen, Elaine Chang, Eias Zahalka, Jeanne Fourie Zirkelbach, Shenghui Tang, Amna Ibrahim, Mallorie H. Fiero, Julia A. Beaver, Kirsten B. Goldberg, Vishal Bhatnagar, Miao Zhao, Paul G. Kluetz, Richard Pazdur, Tiffany K. Ricks, Jingyu Yu, Junshan Qiu, Lijun Zhang
Publikováno v:
Clin Cancer Res
On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Approval was based on the TIVO-3 study, a
Autor:
Pingfu Fu, Monaliben Patel, John J. Pink, Tithi Biswas, Mitchell Machtay, Shufen Cao, Charles A Kunos, Debora S. Bruno, Stanton L. Gerson, David L. Bajor, Nancy L. Oleinick, Shakun Malik, Afshin Dowlati
Publikováno v:
Clin Cancer Res
Purpose: TRC102, a small-molecule base-excision repair inhibitor, potentiates the cytotoxicity of pemetrexed and reverses resistance by binding to chemotherapy-induced abasic sites in DNA. We conducted a phase I clinical trial combining pemetrexed an
Autor:
Mieke Mertens, Barbara Leuchs, Nicolas Hohmann, Oliver Sedlaczek, Meinhard Kieser, Jean Rommelaere, Veronika Frehtman, Ottheinz Krebs, Maximilian Pilz, Volker Daniel, Matthias M. Gaida, Jacek Hajda, Christoph Springfeld, A Mavratzas, Christine E. Engeland, Assia L. Angelova, Guy Ungerechts, Niels Halama, Michael Dahm, Jutta Schreiber, Bernard Huber, Dirk Jäger
Publikováno v:
Clinical Cancer Research. 27:5546-5556
Purpose: To investigate the safety, clinical efficacy, virus pharmacokinetics, shedding, and immune response after administration of an oncolytic parvovirus (H-1PV, ParvOryx) to patients with metastatic pancreatic ductal adenocarcinoma (PDAC) refract
Autor:
Alvin M. Matsumoto, Nima Sharifi, Michael T. Schweizer, Heather H. Cheng, R. Bruce Montgomery, Mary-Ellen Taplin, P.W. Kantoff, Felix S. Chew, Evan Y. Yu, Orpheus Kolokythas, Steven P. Balk, Peter S. Nelson, Brett T. Marck, Elahe A. Mostaghel
Publikováno v:
Clin Cancer Res
Purpose: In metastatic castration-resistant prostate cancer (mCRPC) low serum androgens prior to starting abiraterone acetate (AA) is associated with more rapid progression. We evaluated the effect of AA on androgens in castration-resistant prostate
Autor:
David Marin, Elias Jabbour, Denái R. Milton, Amanda Olson, Gabriela Rondon, Jin S. Im, Rohtesh S. Mehta, Uday R. Popat, May Daher, Felipe Samaniego, Loretta J. Nastoupil, Neeraj Saini, Celina Ledesma, Paolo Anderlini, Muzaffar H. Qazilbash, Qaiser Bashir, Issa F. Khouri, Alison M. Gulbis, Richard E. Champlin, L. Jeffrey Medeiros, Swaminathan P. Iyer
Publikováno v:
Clinical Cancer Research. 27:5847-5856
Purpose: To compare outcomes between patients with relapsed follicular lymphoma who received a nonmyeloablative allogeneic stem cell transplant (alloSCT) and those who received an autologous transplant (autoSCT). Patients and Methods: We evaluated 19
Autor:
Konstantin Penkov, Taofeek K. Owonikoko, Peter M. Ellis, Bruce A. Bach, Anne Sibille, Vasudha Sehgal, Choon Hee Son, Lei He, Jaimee Glasgow, Harry J.M. Groen, Junya Fujimoto, Patricia M. de Groot, Kingston Kang, Martin Dunbar, Lauren Averett Byers, Steven J. M. Gans, Dmitry Bentsion
Publikováno v:
Clinical Cancer Research, 27(14), 3884-3895. AMER ASSOC CANCER RESEARCH
Purpose: This study investigated the efficacy and safety of oral PARP inhibitor veliparib, plus carboplatin and etoposide in patients with treatment-naïve, extensive-stage small cell lung cancer (ED-SCLC). Patients and Methods: Patients were randomi
Autor:
Amy E. DeZern, Alan F. List, Jeffrey E. Lancet, Hannah Newman, Eric Padron, Maria E. Balasis, Mikkael A. Sekeres, Rami S. Komrokji, Anthony M. Hunter, Qianxing Mo, Traci Kruer, Sandrine Niyongere, Markus Ball, Christopher Letson, Aaron T. Gerds, Gail J. Roboz, David A. Sallman, Hailing Zhang, Onyee Chan, David P. Steensma, William Dominguez-Viqueira
Publikováno v:
Clinical Cancer Research. 27:6095-6105
Purpose: Chronic myelomonocytic leukemia (CMML) is a rare leukemia characterized by peripheral monocytosis with no disease-modifying therapies. CMML cells are uniquely hypersensitive to granulocyte-macrophage colony-stimulating factor (GM-CSF) and ro
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Autor:
Rachel E. Sanborn, John E. Leonard, Crystal Mallow, Megan Ann Baumgart, Andreas Schröder, Nashat Y. Gabrail, Aaron S. Mansfield, Jonathan W. Goldman, Maurice Zauderer, Nagashree Seetharamu, JT Beck, Michael Shafique, Elizabeth E. Evans, Desa Rae Pastore, Ramaswamy Govindan, Ernest S. Smith, Kevin M. Chin, Yanyan Lou, Terrence L. Fisher, Vikas Mishra, Alexander I. Spira
Publikováno v:
Clinical Cancer Research. 27:3630-3640
Purpose: The CLASSICAL-Lung clinical trial tested the combination of pepinemab, an IgG4 humanized mAb targeting semaphorin 4D, with the PD-L1 inhibitor avelumab to assess the effects of coupling increased T-cell infiltration and reversal of immune su
Autor:
Bruce A. Littlefield, Elodie Modave, Amy Weaver, Bram Boeckx, Diether Lambrechts, Agnieszka Wozniak, Patrick Schöffski
Publikováno v:
Clinical Cancer Research. 27:3106-3115
Purpose:A randomized phase III study evaluated the efficacy of eribulin versus dacarbazine in patients with advanced liposarcoma and leiomyosarcoma. Improved overall survival (OS) led to approval of eribulin for liposarcoma, but not for leiomyosarcom
Autor:
Jordi Rodon, Joann Lim, Elizabeth A. Sumner, Hira Zain, Di Nguyen, Jack P. Higgins, Vivek Subbiah, Funda Meric-Bernstam, Eric T Williams, Coline Agnes Couillault, Siqing Fu, Timothy A. Yap, Kimal Rajapakshe, Aparna Hegde, Sarina Anne Piha-Paul, Shubham Pant, Michael A. Curran, Priya Bhosale, Priyamvada Jayaprakash, David S. Hong, Thomas F. Wilson, Daniel D. Karp, Ecaterina Ileana Dumbrava, Ly M. Nguyen, Cristian Coarfa
Publikováno v:
Clin Cancer Res
Purpose: As hypoxia can mediate resistance to immunotherapy, we investigated the safety, tolerability, and efficacy of combining evofosfamide, a prodrug that alleviates hypoxia, with ipilimumab, an immune checkpoint inhibitor, in immunologically “c